CCL20 and breast cancer: Through analyzing the cohort of basal breast cancer cases, we found that high CCL20 expression significantly predicted poor OS in the entire cohort of breast cancer patients (not only for patients treated by taxane) (Fig 7A), which, given the key role of CCL20 in modulating chemotherapeutic resistance, may provide an important clue for the design of subsequent new chemotherapy regimens for patients who have received chemotherapy but failed the treatment or are about to receive chemotherapy.